Wednesday, October 27, 2021 – The U.S. Senate yesterday passed H.R. 1899, the Ensuring Compliance Against Drug Diversion Act of 2021, introduced by Congressman Morgan Griffith (R-VA). The bill had previously passed the U.S. House of Representatives on April 15, 2021. Griffith issued the following statement:
“Lapses in the registration of manufacturers, distributors, and sellers of legal opioids may have contributed to the epidemic of abuse and death that has ravaged our communities. My bill, the Ensuring Compliance Against Drug Diversion Act, would reform Drug Enforcement Agency regulations to prevent these lapses from occurring in the future. I am proud that both the House and the Senate have now on a bipartisan basis advanced this measure to improve oversight over opioids and prevent future abuses, and I look forward to its enactment in the near future.”
The Ensuring Compliance Against Drug Diversion Act amends the Controlled Substances Act to prohibit the transfer of any Drug Enforcement Agency registration to manufacture, distribute, or dispense controlled substances without written consent from the agency.